PYXS insider filings

Pyxis Oncology, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-06. Screen PYXS transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 4 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
GordonMD Global Investments LP — 10% owner & GordonMD Long Biased Master Fund LP — 10% owner & GordonMD Long Biased GP LLC — 10% owner & Gordon Craig D — 10% owner21 leg · 5,517,000 sh—2
Civik Thomas — CEO & Chairman of the Board, Director1——1
HUMPHREY RACHEL — Director1——1

Recent insider filings — Pyxis Oncology, Inc.

FiledFormInsiderReported transactionsSource
2026-11-064HUMPHREY RACHEL — DirectorGrant/award (A): 34,500 (derivative) @ $0EDGAR
2026-10-094/AGordonMD Global Investments LP — 10% owner
GordonMD Long Biased Master Fund LP — 10% owner
GordonMD Long Biased GP LLC — 10% owner
Gordon Craig D — 10% owner
Purchase (P): 7,172,000 (derivative)EDGAR
2026-10-024GordonMD Global Investments LP — 10% owner
GordonMD Long Biased Master Fund LP — 10% owner
GordonMD Long Biased GP LLC — 10% owner
Gordon Craig D — 10% owner
Purchase (P): 5,517,000 · Purchase (P): 7,546,766 (derivative)EDGAR
2026-09-084Civik Thomas — CEO & Chairman of the Board, DirectorGrant/award (A): 2,503,050 (derivative) @ $0EDGAR
2026-08-204Dupont Jakob — DirectorGrant/award (A): 46,000 (derivative) @ $0EDGAR
2026-08-144Civik Thomas — Interim CEO, DirectorGrant/award (A): 250,956 (derivative) @ $0EDGAR
2026-07-024Dupont Jakob — DirectorOption exercise (M): 35,000 @ $1.60 · Sale (S): 35,000 @ $3.06 · Option exercise (M): 35,000 (derivative) @ $0EDGAR
2026-03-254Wadhane Jitendra — Prin Fin & Acct OfficerGrant/award (A): 109,461 @ $0 · Grant/award (A): 262,635 (derivative) @ $0EDGAR
2026-03-254Palani Santhosh — DirectorGrant/award (A): 45,867 (derivative) @ $0EDGAR
2026-03-254Cline Darren S — DirectorGrant/award (A): 45,867 (derivative) @ $0EDGAR
2026-03-254HUMPHREY RACHEL — DirectorGrant/award (A): 45,867 (derivative) @ $0EDGAR
2026-03-254HUMPHREY RACHEL — DirectorSale (S): 1,400 @ $0.97 · Sale (S): 200 @ $0.97 · Sale (S): 13,896 @ $1.03EDGAR
2026-03-254Dupont Jakob — DirectorGrant/award (A): 45,867 (derivative) @ $0EDGAR
2026-03-254Metzger Michael A — DirectorGrant/award (A): 45,867 (derivative) @ $0EDGAR
2026-03-254Lewis-Hall Freda C — DirectorGrant/award (A): 45,867 (derivative) @ $0EDGAR
2026-03-254FLAVIN JOHN L — DirectorGrant/award (A): 45,867 (derivative) @ $0EDGAR
2026-02-054Civik Thomas — Interim CEO, DirectorGrant/award (A): 690,131 (derivative) @ $0EDGAR
2025-04-024Wadhane Jitendra — SVP, Chief Accounting OfficerGrant/award (A): 263,782 (derivative) @ $0.98EDGAR
2025-04-024Palani Santhosh — DirectorGrant/award (A): 36,979 (derivative) @ $0.98EDGAR
2025-04-024Connealy Pamela Ann — CFO & COOGrant/award (A): 414,163 (derivative) @ $0.98EDGAR
2025-04-024Sullivan Lara — President ,CEO & CMO, DirectorGrant/award (A): 918,308 (derivative) @ $0.98EDGAR
2025-04-024Civik Thomas — DirectorGrant/award (A): 36,979 (derivative) @ $0.98EDGAR
2025-04-024Cline Darren S — DirectorGrant/award (A): 36,979 (derivative) @ $0.98EDGAR
2025-04-024HUMPHREY RACHEL — DirectorGrant/award (A): 36,979 (derivative) @ $0.98EDGAR
2025-04-024Dupont Jakob — DirectorGrant/award (A): 36,979 (derivative) @ $0.98EDGAR
2025-04-024Metzger Michael A — DirectorGrant/award (A): 36,979 (derivative) @ $0.98EDGAR
2025-04-024Lewis-Hall Freda C — DirectorGrant/award (A): 36,979 (derivative) @ $0.98EDGAR
2025-04-024FLAVIN JOHN L — DirectorGrant/award (A): 36,979 (derivative) @ $0.98EDGAR
2024-12-234Connealy Pamela Ann — CFO & COOGrant/award (A): 310,000 (derivative) @ $0EDGAR
2024-12-234Wadhane Jitendra — SVP, Chief Accounting OfficerGrant/award (A): 150,000 (derivative) @ $0EDGAR
2024-12-234Sullivan Lara — Chief Executive Officer, DirectorGrant/award (A): 1,135,000 (derivative) @ $0EDGAR
2024-11-274Connealy Pamela Ann — CFO & COOPurchase (P): 5,450 @ $2 · Purchase (P): 83,400 @ $1.96EDGAR
2024-06-104Metzger Michael A — DirectorGrant/award (A): 70,683 (derivative) @ $0EDGAR
2024-06-074Palani Santhosh — DirectorGrant/award (A): 6,000 @ $0EDGAR
2024-03-284Connealy Pamela Ann — CFO & COOGrant/award (A): 328,710 @ $0EDGAR
2024-03-284Wadhane Jitendra — SVP, Chief Accounting OfficerGrant/award (A): 131,484 @ $0EDGAR
2024-03-284Sullivan Lara — Chief Executive Officer, DirectorGrant/award (A): 1,071,242 (derivative) @ $3.83EDGAR
2024-03-284Civik Thomas — DirectorGrant/award (A): 44,024 (derivative) @ $3.83EDGAR
2024-03-284Cline Darren S — DirectorGrant/award (A): 35,219 @ $0EDGAR
2024-03-284HUMPHREY RACHEL — DirectorGrant/award (A): 38,741 @ $0EDGAR
2024-03-284Dupont Jakob — DirectorGrant/award (A): 38,741 @ $0EDGAR
2024-03-284Lewis-Hall Freda C — DirectorGrant/award (A): 35,219 @ $0EDGAR
2024-03-284FLAVIN JOHN L — DirectorGrant/award (A): 35,219 @ $0EDGAR
2024-03-134Palani Santhosh — DirectorGrant/award (A): 69,760 (derivative) @ $0EDGAR
2023-12-294Kobayashi Ken — Chief Medical OfficerGrant/award (A): 443,514 (derivative) @ $0 · Grant/award (A): 110,878 (derivative) @ $0EDGAR
2023-11-304Connealy Pamela Ann — CFO and COOTax withholding (F): 36,949 @ $1.40EDGAR
2023-11-174Wadhane Jitendra — Chief Accounting OfficerGrant/award (A): 40,000 @ $0EDGAR
2023-09-284Connealy Pamela Ann — CFO and COOPurchase (P): 8,000 @ $1.87EDGAR
2023-09-274Wadhane Jitendra — Chief Accounting OfficerPurchase (P): 2,500 @ $1.87EDGAR
2023-09-274Connealy Pamela Ann — CFO and COOPurchase (P): 6,426 @ $1.85EDGAR

Recent 8-K events — Pyxis Oncology, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-198-K7.01 — Regulation FD Disclosure
8.01 — Other Events
EDGAR
2026-11-138-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
5.07 — Submission of Matters to a Vote of Security Holders
EDGAR
2026-11-058-K2.02 — Results of Operations and Financial ConditionEDGAR
2026-10-018-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-098-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-088-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-138-K2.02 — Results of Operations and Financial ConditionEDGAR
2026-07-028-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
7.01 — Regulation FD Disclosure
EDGAR
2026-06-158-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-148-K2.02 — Results of Operations and Financial ConditionEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=PYXS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs